 Norwood, MA, Aug. 03, 2020 GLOBE NEWSWIRE -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ: CRBP Corbus or the Company, a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences.The following are the details for the conferences: BTIG Virtual Biotechnology Conference 2020 Event: Fireside Chat Discussion and QA Date and Time: August 10, 2020 at 10:00 AM ET Canaccord Genuity 40th Annual Growth Conference Event: Company Presentation and QA Date and Time: August 13, 2020 at 3:00 PM ETAn audio webcast of the presentations will be accessible on the Events page of the Investors section of the Corbus website, approximately one hour after each event and will be archived for 90 days following the event. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Companys lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 CB2 agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 CB1 inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis NASH, among others. Corbus expects data from its Phase 1 safety study in 2020.Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASHNAFLD. For more information on Corbus clinical programs, please visit here.For more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook.Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Companys product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Companys filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Corbus Pharmaceuticals Contacts:Ted Jenkins, Senior Director, Investor Relations and Corporate Communications Phone: 1 617 415-7745 Email: Smith, Director, Investor Relations and Corporate Communications Phone: 1 617 415-7749 Email: Tartaglia Stern IR, Inc. Phone: 1 212 362-1200 Email: 